Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Ose Immunotherapeutics patents

Recent patent applications related to Ose Immunotherapeutics. Ose Immunotherapeutics is listed as an Agent/Assignee. Note: Ose Immunotherapeutics may have other listings under different names/spellings. We're not affiliated with Ose Immunotherapeutics, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "O" | Ose Immunotherapeutics-related inventors

Anti-cd28 humanized antibodies formulated for administration to humans

The present invention pertains to a novel and advantageous dosage regimen for a humanized pegylated monovalent anti-cd28 fab′ antibody fragment, called “fr104”. This dosage regimen consists of between 0.05 and 1.5 mg/kg body weight of fr104, at a dosing schedule of once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks or once every 6 weeks, once every 7 weeks, once every 8 weeks or once every more than 8 weeks.. ... Ose Immunotherapeutics

Method for inducing early t memory response with short peptides anti-tumor vaccine

The present invention relates to a therapeutic peptide t specific immune therapy for use in the treatment of a cancer of an hla-a2 (human leukocyte antigen a2) positive patient, said treatment comprises a priming period consisting in two to three administrations of said therapeutic peptide t specific immune therapy, thereby inducing a memory t cell response.. . ... Ose Immunotherapeutics

Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis

The present invention relates to a peptide vaccine composition ose-2101 for treatment of brain metastasis in hla-a2 positive patients.. . ... Ose Immunotherapeutics

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation.. ... Ose Immunotherapeutics

Antibodies directed against cd127

The invention relates to antibodies directed against cd127, the alpha chain of the interleukin 7 (il-7) receptor il-7r), and which have antagonist properties for il-7-il-7r interaction, may present cytotoxic activity against cd127 positive cells but do not increase the maturation of dendritic cells (dcs) induced by tslp, a cytokine also using cd127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of cd127 and/or inhibit the il7-induced internalization of cd127. ... Ose Immunotherapeutics

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Ose Immunotherapeutics in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ose Immunotherapeutics with additional patents listed. Browse our Agent directory for other possible listings. Page by